Transforming innovation into novel therapies to address patient needs
Achillion applies expertise in biology and structure-guided design and a deep understanding of patient, clinician, and payer needs to develop innovative treatment solutions aimed at improving patients’ lives. The company’s scientific excellence, integrated capabilities and experienced team position it to successfully advance new products along the entire continuum from the bench to the patient.
Achillion is advancing a novel platform of complement factor D inhibitors for the treatment of complement-related diseases. Leveraging its internal discovery expertise, Achillion has generated a number of potent and specific small molecule compounds with the potential to be administered orally in rare diseases or by sustained delivery, as in treatments for ocular diseases.
Achillion also discovered and developed a comprehensive portfolio of antivirals for the treatment of hepatitis C (HCV), including a second-generation NS5A inhibitor, ACH-3102, a novel nucleotide NS5B polymerase inhibitor, ACH-3422, and a NS3/4A protease inhibitor, sovaprevir. Achillion established a worldwide collaboration with Janssen Pharmaceuticals (a Johnson & Johnson company) for the further development and commercialization of these compounds. A key objective of the collaboration is to combine these assets with Janssen's HCV portfolio in order to create an optimized, short-duration, highly effective, oral treatment regimen for all HCV patients.
Achillion is headquartered in New Haven, Connecticut. Achillion's common stock trades on the NASDAQ Global Select Market under the symbol: ACHN.